Home Cart Sign in  
Chemical Structure| 1577222-14-0 Chemical Structure| 1577222-14-0

Structure of Diroximel fumarate
CAS No.: 1577222-14-0

Chemical Structure| 1577222-14-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Diroximel fumarate is an oral prodrug of monomethyl fumarate, with activity similar to dimethyl fumarate, suitable for research on multiple sclerosis. Diroximel fumarate is a Nrf2 activator that alleviate MGO-induced pain hypersensitivity.

Synonyms: ALKS 8700; BIIB098

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Diroximel fumarate

CAS No. :1577222-14-0
Formula : C11H13NO6
M.W : 255.22
SMILES Code : O=C(OC)/C=C/C(OCCN1C(CCC1=O)=O)=O
Synonyms :
ALKS 8700; BIIB098
MDL No. :MFCD28502263
InChI Key :YIMYDTCOUQIDMT-SNAWJCMRSA-N
Pubchem ID :73330464

Safety of Diroximel fumarate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Jurkat cells 25 μg/mL 72 hours Assess the effect of DRF on Jurkat cell metabolic activity, showing significant inhibition at 25 μg/mL. FEBS Open Bio. 2025 May;15(5):754-762
BV-2 murine microglia 100 μM Evaluate the effect of DRF on LPS-activated BV-2 cell proliferation, showing no significant effect at the highest tested dose (100 μM). FEBS Open Bio. 2025 May;15(5):754-762
human fetal astrocytes 2.5 µM 24 hours Evaluated gene expression changes, found that the effects of DRF and IDMF on gene expression differed from those of MMF, with IDMF having the largest effect on gene expression Pharmaceuticals (Basel). 2022 Apr 11;15(4):461

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice (C57BL/6 and Nrf2KO) MGO-induced mechanical and cold hypersensitivity model Oral gavage 60 mg/kg or 100 mg/kg Once daily for 5 days To assess DRF's protection against MGO-induced nociception; results showed DRF (100 mg/kg) significantly attenuated mechanical and cold hypersensitivity, dependent on Nrf2 pathway. Diabetes. 2025 May 1;74(5):827-837
Sprague-Dawley rats Chronic constriction injury (CCI) of the sciatic nerve Oral 100 mg/kg Once daily for 7 days Diroximel fumarate alleviated neuropathic pain and reduced TSPO upregulation. Brain Behav Immun. 2025 Jan;123:11-27

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.92mL

0.78mL

0.39mL

19.59mL

3.92mL

1.96mL

39.18mL

7.84mL

3.92mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories